Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2005 | Review Article

Highlights of the Annual Congress of the European Association of Nuclear Medicine, Helsinki 2004, and a dash of horizon scanning

Author: Peter J. Ell

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2005

Abstract

The Annual Congress of the European Association of Nuclear Medicine represents the major scientific and professional event in the field of nuclear medicine in Europe. Specialists from all allied professions meet to discuss the latest findings and discoveries. A very large industrial exhibition demonstrates the latest technological innovations and developments. This Highlights Lecture summarises the scientific and medical advances discussed at this important gathering. The lecture covers a significant proportion of the data presented and/or discussed in up-to-date reviews, and places some of the trends encountered in the context of the evolution of the field as a whole. There is much food for thought in most areas of nuclear medicine: advances in instrumentation and data processing, progress in radiochemistry and pharmacy, novel diagnostics and therapeutics, and new insights in known areas of clinical application such as neurology and psychiatry, cardiology, oncology, endocrine disorders, paediatrics, nephro-urology and musculoskeletal disorders. This Highlights Lecture is, however, only a brief résumé of the vast amount of data discussed, which can be found in much greater detail in the Congress Proceedings, published as volume 31, supplement 2 of Eur J Nucl Med Mol Imaging in August 2004.

Wastie ML, Latief KH. Gadolinium: named after Finland’s most famous chemist. Br J Radiol 2004;77:146–7.CrossRefPubMed

Moses WW. Time of flight in PET revisited. IEEE Trans Nucl Sci 2003;50(5):1325–30.CrossRef

Visvikis D, Ell PJ. Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S106–16.PubMed

Matsumoto K, Kitamura K, Mizuta T, Tanaka K, Watanabe E, Yamamoto S, et al. SET-3000 G/X: NEMA performance evaluation of the SET-3000 G/X system, the new high-resolution and the large axial field of view clinical tomograph. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S399–400.CrossRef

Boerdijk S, Willemsen ATM, Pruim J. The evaluation of 3D 18-FDG wholebody PET scanning. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 2:S212.

Patrina JIS, Faria DAB, Araujo SCR, Fontes FRG, Oliveira JMA, Costa DC. Standardized uptake values (SUVs) calculated from [¹⁸F]FDG PET studies do not differ between 2D and 3D acquisition mode. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S212.

Meeuwissen S, Buijs S, Dekkers E, Haaring C, Hoekstra A, van Isselt JW. The inter-observer variation for SUV determined by hand drawing ROI at the PET. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S212.

Visvikis D, Barret O, Turzo A, Fryer TD, Bizais Y, Carson K, et al. Feasibility of image-derived respiratory gating of FDG PET datasets. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S230.

O’Connor MK, Rhodes DJ, Phillips SW, Collins DA. Preliminary results with a cadmium–zinc–telluride gamma camera for scintimammography. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S243.

10.

de Visser M, Erion J, Reubi JC, Visser TJ, Krenning EP, de Jong M. New bombesin analogues showing that the rat GRP receptor is not a good model for the human receptor. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S263–4.

11.

Nock BA, Maina T, Nikolopoulou A, Zhang H, Reubi JC, Maecke HR. Interspecies differences during comparative evaluation of [¹¹¹In]Z-070 and [^99mTc]Demobesin 1 in rat or human origin GRP-R-expressing cells and animal models. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 2:S280.

12.

Hassoun W, Valette H, Bottlaender M. In vitro characterization of 2-[¹⁸F]F-A-85380, a PET ligand for alpha 4 beta 2 nicotinic receptors. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S288.

13.

Sarda-Mantel L, Michel JB, Loiseau P, Martet G, Meulemans A, Vrigneaud JM, et al. ^99mTc-Hynic-Annexin-V and ¹¹¹In-antimyosin-antibody myocardial uptake after permanent coronary ligature and ischemia-reperfusion in rats. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S293.CrossRef

14.

Breeman WAP, de Blois RH, de Jong M, Krenning EP. Rapid preparation of ⁶⁸Ga-labelled DOTA-conjugated peptides for PET imaging. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S385.

15.

de Visser M, Breeman WAP, Mäcke HR, Zhang H, Bernard HF, Krenning EP, de Jong M. ¹¹¹In versus ⁶⁸Ga, in vivo comparison using new bombesin analogues. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S257.

16.

Hoffend J, Mier W, Schmidt K, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss LG, Haberkorn U. In vivo characterization of gallium-68-DOTA-albumin, a generator-produced PET blood-pool tracer. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S257–8.

17.

Hofmann M, Machtens S, Stief C, Stief C, Länger F, Boerner AR, et al. Feasibility of Ga-68-DOTABOM PET in prostate carcinoma patients. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S253.

18.

Baum RP, Söldner J, Schmücking M, Niesen A. Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-TYR3-OCTREOTATE (Y-90 DOTA-TATE) in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 2:S238.

19.

Lu SY, Watts P, Chin FT, Hong J, Musachio JL, Haswell SJ, Pike VW. Exploration of a micro-reactor for the synthesis of NCA ¹¹C- and ¹⁸F-labeled carboxylic esters. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S248.

20.

Maina T, Sultan D, Nock BA, Galanis A, Cordopatis P, Rogers BE. [^94mTc]Demotate 1 as a PET tracer in the sstr2-targeted imaging of tumors: first results in sstr2-expressing cells and animal models. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S209.

21.

Laznickova A, Laznicek M, Maina T, Nock B. Distribution and elimination analysis of [^99mTc]Demotate 1 in rats. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S378–9.CrossRef

22.

Kersemans K, Joos C, Bauwens M, Kersemans V, Mertens JJR. Synthesis of [¹⁸F]-2-fluoromethylphenylalanine, a new potential tracer for tumor specific diagnosis in humans with PET. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S219.

23.

Mertens JJR, Kersemans V, Lahoutte T, Bauwens M, Joos C, Kersemans K, Slegers G. Radioiodo-D-2-l-pheylalanine, a new tumour specific tracer for diagnosis and systemic radionuclide therapy. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S220.

24.

Rattat D, Terwinghe C, Mortelmans L, Verbruggen A. Comparison of labelling and biodistribution of “classic” ^99mTc-DTPA with ^99mTc(DTPA)(CO)₃ and ^99mTc(DTPA)(CO)₂(NO) Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S210.

25.

Nakamura K, Kubo A, Hnatowich DJ. Successful tumor targeting in mice with ^99mTc-antisense DNA. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S210.

26.

Termaat MF, Raijmakers PGH, Scholten HJ, Patka P, Bakker FC, Haarman HJT. The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis; systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S276–7.

27.

Garcia JR, Simo M, Soler M, Perez G, Lopez S, Lomena F. Positron emission tomography with ¹⁸F-fluorodeoxyglucose and bone scintigraphy with ^99mTc-MDP mismatch in detection of bone metastases from non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S350–1.

28.

Büyükdereli G, Erman T, Kara O, Kibar M. Tc-99m MIBI findings of acute vertebral fractures in traumatic patients: preliminary results. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S438.

29.

Paganelli G, Trifirò G, De Cicco C, Travaini LL, Baio SM, Prisco G, et al. Lymphoscintigraphy and sentinel node identification after excisional breast biopsy. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S244.CrossRef

30.

Estourgie SH, Valdés Olmos RA, Nieweg OE, Hoefnagel CA, Rutgers ET, Kroon BBR. Reproducibility of sentinel node lymphoscintigraphy after excisional biopsy of breast lesions. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S296.

31.

van Rijk MC, Tanis PJ, Valdés Olmos RA, Nieweg OE, Rutgers EJ, Kroon BB, Hoefnagel CA. Sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S295–6.CrossRef

32.

Carpentier P, Gauthier H, Bercez C, Chauvet MP, Sulman C, Giard S. The changing costs of treatment for early-stage breast cancer in France: comparison between sentinel lymph node biopsy and conventional axillary lymph node dissection. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 2:S451.

33.

Rubello D, Pelizzo MR, Boni G, Schiavo R, Vaggelli L, Villa G, et al. Long-term results of the multi-institutional Italian GISCRS study group on minimally invasive radioguided surgery (MIRS) of primary hyperparathyrodism (PHPT) patients with “the low ^99mTc-sestamibi dose technique”. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S245.

34.

Härkönen RA, Parviainen S, Mäki MT. Detection of pulmonary emboli by V/Q planar scintigraphy, V/Q SPET and helical CT. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S254.

35.

Miniati M, Monti S, Salvadori M. An alternative approach to ventilation-perfusion scintigraphy in the diagnosis of pulmonary embolism. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S213.

36.

Kropp J, Prescher Y, Beuthien-Baumann B, Andreess M, Oehme L, Schellong S. Experience of V/P tomography. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2: S213.

37.

Bajc M. Tomographic V/P-quotient scintigraphy. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S213.

38.

Acampa W, Petretta M, Spinelli L, Ibello F, De Lauro F, Sansone L, et al. Survival benefit after revascularization is independent on left ventricular ejection fraction improvement in patients with previous myocardial infarction and viable myocardium. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S284.

39.

Acampa W, Spinelli L, Petretta M, De Lauro F, Ibello F, Pellegrino T, et al. Prognostic value of dobutamine stress echocardiography and sestamibi SPECT in medically treated patients after uncomplicated acute myocardial infarction. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 2:S283–4.

40.

Miller T. Asymptomatic diabetic patients. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S214.

41.

Ferro A, Acampa W, Petretta M, Ibello F, Salvatore M, Cuocolo A. A prospective multi-center trial to identify the prevalence of inducible ischemia in patients presenting with diabetes and without known coronary artery disease: preliminary results. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S302.

42.

Dumont M, Côté C, Lefebvre L, Lacourcière Y. Detection of silent coronary artery disease in hypertensive asymptomatic patients with or without type 2 diabetes mellitus by dipyridamole stress Tc-99m sestamibi myocardial imaging Spect. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S304.CrossRef

43.

Calcagni ML, Prior JO, Koehli M, Monbaron D, Ruiz J, Bischof Delaloye A. Prevalence of myocardial perfusion defects in symptomatic and asymptomatic diabetic patients. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S268.

44.

Estorch M, Narula J, Mena E, Flotats A, Camacho V, Fuertes J, et al. MIBG imaging and pharmacological intervention: effect of a single dose of amitriptyline on regional cardiac MIBG uptake. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S292.CrossRef

45.

Viljanen APM, Virtanen KA, Järvisalo MJ, Hällsten K, Rönnemaa T, Iozzo P, et al. Effects of rosglitazone and metformin on femoral subcutaneous adipose tissue blood flow and glucose uptake in patients with type 2 diabetes. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S286–7.

46.

Vlajkovic M, Rajic M, Ilic S, Bogicevic M, Petronijevic V, Miljkovic P, Golubovic E. Radionuclide assessment of bladder function in children with primary monosymptomatic and non-monosymptomatic nocturnal enuresis Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S271.

47.

Minn H, Otonkoski T, Huopio H, Näntö-Salonen K, Eskola O, Parkkola R, et al. Diagnosis of focal infantile hyperinsulinism with FDOPA PET. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S270–1.

48.

Antke C, Koestering K, Kley K, Beu M, Brehm M, Larisch R, et al. Influence of intracoronary stem cell transplantation on myocardial viability in chronic myocardial infarction: a study with [F-18]FDG-PET and Tc-99m tetrofosmin SPECT. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S274.

49.

Hofmann M, Wollert K, Meyer GJ, Boerner AR, Arseniew L, Hertenstein B, et al. Bone marrow cell homing after intracoronary transplantation imaged by feasibility of Ga-68-DOTABOM PET in prostate carcinoma patients. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S274.

50.

Signore A, Bonanno E, De Toma G, Arca M, D’Alessandria C, Marcoccia A, et al. ^99mTc-Interleukin-2 scintigraphy for imaging unstable atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 2:S203.CrossRefPubMed

51.

Buchhorn HM, Beck R, Saur D, Seidl C, Becker KF, Schwaiger M. Bioluminescent molecular imaging of the effect of Bi-213-immunotherapy in vitro and in an intraperitoneal xenograft model using firefly luciferase transfected gastric cancer cells (HSC45-M2-luc). Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S297.CrossRef

52.

Frokjaer VG, Mortensen EL, Adams KH, Haugbä S, Pinborg LH, Svarer C, et al. The personality traits vulnerability and self-discipline are associated with regional 5-HT2A-receptor binding in healthy subjects. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S228.

53.

Koch W, Poepperl G, Welsch J, Hamann C, Radau PE, Tatsch K. Extended studies of the striatal uptake of [Tc-99m]NC100697 in healthy volunteers. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S209.

54.

Vander Borght T, Tolosa E, on behalf of DaTSCAN CUPS Study Group Assessment of ¹²³I-ioflupane (DaTSCAN^TM) diagnostic accuracy by a two year follow-up study of patients with clinically uncertain parkinsonism. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 2:S247.

55.

Poepperl G, Goldbrunner R, Gildehaus FJ, Tanner P, Tatsch K. [F-18]FET PET for monitoring the effects of convection enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S234.

56.

Mathis CA. The recent advances in tracers for beta-amyloid imaging in vivo. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S266.

57.

Schiepers C, Chen W, Huang SC, Kamdar N, Silverman DHS, Cloughesy T, et al. ¹⁸F-DOPA kinetics of brain tumors. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S236.

58.

Buck AK, Schirrmeister H, Kratochwil C, Glatting G, Arslandemir C, Halter G, et al. FLT-PET for staging of lung cancer and detection of malignant lung tumours—a comparison to FDG-PET. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S204.CrossRef

59.

Kabasakal L, Sager S, Nisli C, Maecke H, Onsel D, Uslu I. Clinical experience with Tc-99m HYNIC/TOC and Tc-99m HYNIC/TATE in somatostatin receptor positive lesions: preliminary report. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S358.CrossRef

60.

Hubalewska A, Fröss K, Staszczak A, Huszno B, Szbiński P, Kulig J, et al. Detection of somatostatin receptor-positive neuroendocrine tumours using ^99mTc-EDDA/HYNIC-TATE—two-year experience. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S214.

61.

Gotthardt M, Béhé MP, Rinke A, Herbst B, Pfestroff A, Goecke J, et al. In-111-DTPA-dGlu1-Minigastrin in comparison to In-111-DTPA-dPhe1-Octreotide in 87 patients with neuroendocrine tumors Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S214–5.

62.

Di Santo G, Filippi L, Longo F, Remediani S, Trafficante D, Magnolfi E, et al. Comparison of 111-In-pentetreotide versus 18-FDG-PET to detect thymoma residual disease after therapy. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S215.

63.

Baath M, Aspelin P, Kolbeck K, Forslow U, Svensson L, Danielsson R. Somatostatin receptor scintigraphy with 99m-Tc-depreotide (NeoSPECT) in the diagnosis of primary lung cancer. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S215.

64.

Szalus N, Dziuk EJ, Chcialowski A, Zabicka M, From S. ^99mTc-Depreotide scintigraphy and fusion imaging of SPET and CT in the evaluation of malignant pulmonary nodules and metastases. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S215.

65.

Van Den Bossche B, D’haeninck E, De Vos F, Dierckx RA, Van Belle S, Bracke M, et al. Oestrogen mediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with ^99mTc-depreotide. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S293–4.CrossRef

66.

Jarnet D, Denizot B, Bitar A, Bardiès M, Lisbona A, Jallet P In-vivo uses of thermoluminescent dosimetric threads: validation for internal immunoradiotherapy and external irradiation uses. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S282.

67.

Ferrer L, Grealou Y, Autret D, Gaudaire S, Brunet G, Delpon G, et al. A new ImageJ plugin to correct for partial effect volume. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S230.

68.

Visser EP, Postema EJ, van de Ven BMF, Visschers SJ, Buijs WCA. Software package for integrated scintigram data processing in internal dose assessment. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S472.

69.

Glatting G, Landmann M, Kull T, Wunderlich A, Blumstein NM, Reske SN, et al. Development of an interactive software tool to simplify radiation dosimetry before therapy with unsealed radionuclides. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S472.

70.

Chiesa C, Villaggi E, Albertini F, Coliva A, Ruberto T, Fracassi S, et al. Dosimetry in myeloablative treatment with ⁹⁰Y anti CD22 MoAb in refractory non-Hodgkin’s lymphoma—evaluation of waiting time before stem cell reinfusion. Eur J Nucl Med Mol Imaging 2004; 31 Suppl 2:S473.

71.

Jönsson H, Mattsson S. Survey of methods for radioiodine therapy of hyperthyroidism in Sweden. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S262.

72.

Chiavassa S, Bardiãs M, Guiraud-Vitaux F, Bruel D, Jourdain JR, Franck D, et al. OEDIPE: a personalized dosimetric tool associating voxel-based phantoms with MCNPX. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S258.CrossRef

73.

Divoli A, Spinelli A, Chittenden S, Dearnaley D, Flux G. Whole-body dosimetry for targeted radionuclide therapy using spectral analysis. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S259.

74.

Kartachova M, Valdes Olmos R, Haas R, Hoebers F, vd Brekel M, v Zandwijk N, et al. ^99mTc Hynic-rh-Annexin V SPECT/CT matching for evaluation of tumour apoptotic changes in the course of radiotherapy and/or chemotherapy. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S276.

75.

Paganelli G, Trifirò G, De Cicco C, Travaini LL, Baio SM, Prisco G, et al. Lymphoscintigraphy and sentinel lymph node identification after excisional breast biopsy. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S244.CrossRef

76.

Eary JF, Brenner W, Vernon C, O’Sullivan F. Tumor heterogeneity in sarcoma patients is a significant predictor of survival. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S232.

77.

Verwijnen SM, Sillevis Smit PAE, Hoeben RC, Krenning EP, de Jong M. Cell death induced by ganciclovir or ¹⁷⁷Lu-DOTA-octreotate treatment after gene therapy in vitro in rat and human glioma cell lines. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S235.

78.

Wiseman GA, Witzig TE. Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S221.

79.

Tennvall JG, Lindén O, Garkavij M, Kurkus J, Cavallin-Ståhl E, Ohlsson T, et al. A novel platform for radioimmunotherapy. Extracorporeal depletion of biotinylated and ⁹⁰Y-labeled anti-CD20 in patients with refractory B-cell lymphoma. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S221.

80.

Bombardieri E, Canevari S, Coliva A, Luison E, Zacchetti A, Strinchini A, et al. Preclinical validation of ⁹⁰Y-MOv18 for radio-immunotherapy of ovarian carcinomas. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S265.

81.

Sacchetti GM, Leva L, Baiocco C, Rudoni M, Loi G, Dominietto M, et al. Fusion imaging with ^99mTc sestamibi SPET and CT in the delineation of planning target volume (PTV) for 3D-conformal radiotherapy of NSCLC. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S275.

82.

Schmuecking M, Baum RP, Liesenfeld SM, Scheithauer M, Presselt N, Schneider CP, et al. Integration of F-18 FDG PET in clinical trials for multi-modality treatment of non small cell lung cancer: what is the impact of PET in molecular radiation treatment planning. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S205.

83.

Konrad G, Korenjak C, Rausch H, Jank J, Baumgartner S, Primik F, et al. Performance of radiation therapy planning using a fused data set from an integrated PET/CT system. Eur J Nucl Med Mol Imaging 2004;31 Suppl 2:S484.

Title: Highlights of the Annual Congress of the European Association of Nuclear Medicine, Helsinki 2004, and a dash of horizon scanning
Author: Peter J. Ell
Publication date: 01-01-2005
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2005
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1720-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Highlights of the Annual Congress of the European Association of Nuclear Medicine, Helsinki 2004, and a dash of horizon scanning

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2005

Imaging of the corpus striatum without any activity at 192 MBq 18F-fluorodeoxyglucose PET after intoxication

Sestamibi scintigraphy reveals adenocarcinoma of the lung

Molecular imaging of atherosclerotic plaques with technetium-99m-labelled antisense oligonucleotides

The impact of PET scanning on management of paediatric oncology patients

18F-FDG PET in children with lymphomas

Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer